Welcome! The Bloomington Life Sciences Partnership is a collaborative effort dedicated to continued life sciences business growth in greater Bloomington, Indiana - a nationally recognized leading metro area in medical devices, contract pharma, biotechnology, basic research and life sciences workforce development.
Johnson Center for Innovation and Translational Research announces new name, expanded mission
Nov20

Johnson Center for Innovation and Translational Research announces new name, expanded mission

FOR IMMEDIATE RELEASE BLOOMINGTON, Ind. — A monthslong effort to shift the Johnson Center for Entrepreneurship in Biotechnology’s mission is complete, as it now boasts a new name, a broader base of campus constituents and an updated website. The organization is now known as the Johnson Center for Innovation and Translational Research, or JCITR. The new name was approved by the Indiana University Board of Trustees in October and recently made official by President Michael A. McRobbie, said Keith R. Davis, the center’s director. The move not only addressed a need to lessen confusion with its cross-campus counterpart, the Johnson Center for Entrepreneurship and Innovation at the Kelley School of Business. It also reflects an expanded mission to serve all schools, departments and disciplines throughout the Bloomington campus, rather than only those ventures related to biotechnology or other fields within the College of Arts and Sciences. Yet JCITR’s core directive is unchanged. It aims to boost the participation of faculty, researchers and students in translational research and the commercialization of research discoveries by working with industry partners and creating new companies. “Our new name truly captures the core focus of our mission to enhance innovation across the Bloomington campus and will provide an identity for our unique position within IU’s research community,” Davis said. “We hope faculty will come to recognize JCITR as the place where they can get hands-on assistance with building a translational research program and commercializing their discoveries.” Vice Provost for Research Rick Van Kooten said the move reinforces IU’s commitment through its Bicentennial Strategic Plan to build a prosperous and innovative Indiana, in part by establishing a culture of “building and making” statewide. “I am truly excited that the expertise of the Johnson Center is now broadening to encompass the entire Bloomington campus,” Van Kooten said. “Innovation and translational research are key drivers of research excellence. The skills and services offered through JCITR are invaluable to IU researchers, particularly as we move forward with our Grand Challenges program and a new Emerging Areas of Research program.” Members of JCITR’s staff, or “discovery team,” work to make it easy and efficient for faculty to bring their ideas or inventions to market while continuing to focus on their core strengths in basic research. Such duties include: Working with faculty to identify current and new research that can attract commercial contracts or be translated into products that may lead to the launch of Spin Up companies or startup ventures; Collaborating with the IU Research and Technology Corp. and Office of Research Administration to help faculty submit grant applications; Identifying industry partners and negotiating industry contracts in concert with...

Read More
Novo Nordisk to acquire Calibrium LLC and MB2 LLC
Aug28

Novo Nordisk to acquire Calibrium LLC and MB2 LLC

Acquisition expands Novo Nordisk’s portfolio of projects within diabetes and obesity Bagsværd, Denmark, 27 August 2015 – Novo Nordisk today announced that it has entered into a definitive agreement under which Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Indiana, US. Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. The acquisition will expand Novo Nordisk’s portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk’s research presence in the US. Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk says: “We are always on the lookout for ways to strengthen our leadership position within therapeutic proteins. This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fit very well with our aspirations within diabetes and obesity.” Dr Richard DiMarchi, chief scientific officer and co-founder of Calibrium and MB2 says: “It’s an honour to join the global Novo Nordisk research community. Their intense focus on metabolic diseases, which over the years has led to numerous breakthrough proteinbased medicines, aligns perfectly with my career-long priorities. I’m optimistic that together we can create novel, transformative therapies in the fight against the global epidemic of diabetes and obesity.” The parties have agreed not to disclose the financial details of the transactions. The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter of 2015.   About Calibrium and MB2 Calibrium is an emerging biopharmaceutical company focused on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, chief executive officer, and Richard DiMarchi, PhD, chief scientific officer. MB2 is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class, mixed agonist drugs for the treatment of diabetes and obesity. MB2 was co-founded by Kent Hawryluk, chief executive officer and Richard DiMarchi, PhD, chief scientific officer. Both companies are privately held and located in Carmel, IN, US. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube...

Read More
Sintact Medical Systems Receives NSF SBIR Grant
Aug12

Sintact Medical Systems Receives NSF SBIR Grant

Phase I grant will advance development of Sintact’s surgical film, which prevents internal scar formation Bloomington, IN – August 12, 2015 – Sintact Medical Systems, a startup developing an implantable film that prevents internal scar formation following surgery, announced today that the company was selected for a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant. In addition to the $150,000 Phase I grant, Sintact was awarded $50,000 in matching funds from Elevate Ventures in partnership with the Indiana Economic Development Corporation (IEDC).   The collective funds will contribute to the company’s ongoing testing and development of a non-resorbable film designed to separate and protect internal organs from scar formation and scar-related defects—complications that frequently occur after a number of common surgeries.   “It’s exciting to get this kind of validation and support from an organization like the NSF SBIR program, not to mention the additional contribution from Elevate Ventures and the IEDC,” said Sintact CEO Erik Robinson. “These organizations have provided an incredible opportunity that will enable us to make substantial progress toward bringing our technology to market and ultimately improving patients’ lives.”   Phase I of the NSF SBIR grant program is designed as a “proof-of-concept” grant, which can be followed by a larger development grant of $750,000. For the initial phase, Sintact plans to conduct a three-month animal study—a longer version of a study Robinson performed during his doctoral work at Northwestern University in collaboration with Ann & Robert H. Lurie Children’s Hospital of Chicago, which demonstrated a reduction in scar formation of 86 percent.   In addition to seeking out grant funding, Robinson has advanced the commercialization of Sintact’s technology by participating in various programs that support startups, which he feels ultimately helped them secure the grant.   “We’ve been fortunate to get involved in a number of programs that exist to support companies like ours, and these have been an invaluable resource,” Robinson said. “Not only have they helped connect us to mentors, investors and experts in our field who have been instrumental in our growth, but they’ve also helped position us as an attractive investment and a strong candidate for grants like this one.”    Sintact was a member of the 2014 class of Health Wildcatters, a Dallas-based healthcare startup accelerator program. The company has also been supported by VentureWell, an organization out of Massachusetts that helps commercialize innovations developed at colleges and universities, and iBIO Institute’s PROPEL Center, a Chicago-based effort to increase success rates of life science startups.     “It’s wonderful to see Sintact making such great progress since the program,” said Health Wildcatters CEO Hubert Zajicek. “They have...

Read More
Cook Pharmica Grows in Monroe County
Jul20

Cook Pharmica Grows in Monroe County

BLOOMINGTON, Ind. (July 20, 2015) – Cook Pharmica, LLC, a privately-held contract development and manufacturing organization serving the biopharmaceutical industry, announced plans to expand its operations here, creating up to 70 new jobs by 2020.   The company, which is a wholly-owned subsidiary of Bloomington, Indiana-based Cook Group, will invest $28 million to renovate and equip its facility in Bloomington, which is built on the grounds of the former RCA television assembly plant. With the addition of an additional drug product line, the company will fill drug product into syringes, vials (both liquid and lyophilized) and cartridges for Cook Pharmica’s clients. Readiness activities for the new line have already begun, with plans to have the new line operating in early 2017. With its additional capacity, Cook Pharmica will better serve the growing, global biopharmaceutical industry.   “With a $59 billion economic impact in Indiana, the strength of our life sciences industry has a tremendous effect throughout the state,” said Governor Mike Pence. “Here in Indiana, we’re passionate about developing products that make our world a healthier place. We offer the business environment companies like Cook Pharmica need to thrive and in turn, create excellent jobs for Hoosiers.”   Cook Pharmica currently employs 575 associates, part of more than 13,000 Cook Group employees worldwide, and has already begun hiring for its growth. Interested applicants may apply via the careers tab on the company’s website at www.cookpharmica.com.   “Cook was founded in Bloomington more than a half century ago, and we are thrilled to continue our company’s deep connection with the state of Indiana and the city of Bloomington,” said Tedd Green, president of Cook Pharmica. “Working with our partners at the Indiana Economic Development Corporation and the city of Bloomington, this expansion will continue Cook’s commitment to providing world-class biopharmaceutical manufacturing services to customers here and around the world.”   The Indiana Economic Development Corporation offered Cook Pharmica, LLC up to $275,000 in conditional tax credits and up to $400,000 in training grants based on the company’s job creation plans. These incentives are performance-based, meaning until Hoosiers are hired, the company is not eligible to claim incentives. The city of Bloomington approved additional incentives at the request of the Bloomington Economic Development Corporation.   “Cook Pharmica is an economic force in Bloomington, attracting continued national and international recognition of our life sciences sector,” said Bloomington Mayor Mark Kruzan. “Cook Pharmica’s commitment to expansion in equipment, site improvements and workforce and the city’s support through this tax abatement will further solidify the appeal of Bloomington to a talented workforce, attract additional private sector investment and increase the awareness of Bloomington’s economic...

Read More
BioCrossroads New Venture Competition Announces 2015 Call for Entries
Jul02

BioCrossroads New Venture Competition Announces 2015 Call for Entries

BioCrossroads New Venture Competition Announces 2015 Call for Entries The BioCrossroads New Venture Competition, an early stage business competition awarding more than $60,000 in prizes to life sciences and health information technology companies, is now accepting applications at www.biocrossroads.com. Since 2012, the competition has awarded more than $180,000 to twelve start-up companies which have been able to secure nearly $7 million in follow-on funding.   Early-stage biotechnology, pharmaceutical, medical device, diagnostic, ag-biotech, and health information technology companies developing innovative products and platforms are eligible to apply for the New Venture Competition. For consideration, companies must either be Indiana-based or be able to demonstrate a significant Indiana presence.   The winner receives a cash prize of $25,000 and receives access to the Indiana Seed Fund II staff and the fund’s network of resources to provide business planning and early-stage strategic support. They will also have the opportunity to make a presentation to the ISFII investment committee. The fund has invested in several of the previous winners, collectively totaling over $1 million.   The winner will be announced at the Indiana Life Sciences Summit Innovation Capital Day on October 14, 2015 and have an opportunity to pitch their business to the conference audience. Second and third place companies will be awarded cash prizes of $15,000 and $10,000 respectively. There will also be a Pre-Venture prize of $10,000 for a promising technology that is very early in its development.   Applications are available at www.biocrossroads.com and must be submitted by August 17, 2015. Companies invited to the next round will be notified by August 28 and must submit their pitch deck by September 11, 2015. Presentations will be held from September 14-18, 2015. The finalists will then present to a panel of expert judges before the Indiana Life Sciences Summit on Wednesday, Oct. 14.   Previous Winners include: Anagin, Dianotes, and Spensa Technologies. Please follow and like...

Read More
Cook Medical welcomes progressive Medical Device Single Audit Program
Jun16

Cook Medical welcomes progressive Medical Device Single Audit Program

Bloomington, Ind. — Cook Medical is pleased to be one of the global medical device companies to collaborate internationally with regulatory authorities on the Medical Device Single Audit Program (MDSAP).   The value of developing a global program to audit and monitor medical device manufacturing for patient safety was recognized at the International Medical Device Regulators Forum inaugural meeting in 2012. That meeting led to the creation of MDSAP.   MDSAP International Coalition Organizations: US Food and Drug Administration (FDA) Health Canada Therapeutics Goods Administration (TGA) Australia Agência Nacional de Vigilância Sanitária (ANVISA) Brazil Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) Japan   “This progressive approach to regulatory oversight is very exciting,” said Pete Yonkman, president of Cook Medical. “We recognize that good collaboration among regulatory agencies and industry enables more efficient and flexible use of both regulatory and company resources.”   The MDSAP enables regulatory oversight of manufacturers’ quality management systems while minimizing the regulatory burden on industry. It also promotes more efficient and flexible use of regulatory resources through work sharing and mutual acceptance among regulators while respecting the sovereignty of each authority. It also leverages, where appropriate, existing conformity assessment structures.   The Cook Medical plant in Limerick, Ireland, was chosen to trial this new auditing approach. The facility, which employs over 800 staff, underwent a two-day initial certification audit in April, which was led by TÜV SÜD of Germany. It is the first Irish site to take part in MDSAP. This audit is one of six global MDSAP audits to date.   About the Medical Device Single Audit Program: It is based on a three-year audit cycle. The initial certification audit constitutes a stage-one and stage-two audit of a quality management system. A partial surveillance audit takes place in each of the following two years. A complete recertification audit is performed after three years. About Cook Medical Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at www.cookmedical.com, and for the latest news, follow us on Twitter and LinkedIn.   Source: Cook Medical, https://www.cookmedical.com/newsroom/cook-medical-welcomes-progressive-medical-device-single-audit-program/ Please follow and like...

Read More